Sinopharm Subsidiary's Salt Benzylhydrazine Tablet Passes Generic Drug Consistency Evaluation Today

GateNews
According to an announcement today (May 26), Sinopharm subsidiary Shandong Jingfeng Pharma received approval from the National Medical Products Administration for its salt benzylhydrazine tablet (2mg) to pass generic drug quality and efficacy consistency evaluation. The drug is a Category A medical insurance product and is commonly used to treat Parkinson's disease.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments